No connection

Search Results

ACB vs ADAG

ACB
Aurora Cannabis Inc.
BEARISH
Price
$3.43
Market Cap
$194.5M
Sector
Healthcare
AI Confidence
85%
ADAG
Adagene Inc.
BULLISH
Price
$4.13
Market Cap
$194.7M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ACB
--
ADAG
--
Forward P/E
ACB
-31.18
ADAG
-5.74
P/B Ratio
ACB
0.49
ADAG
5.14
P/S Ratio
ACB
0.52
ADAG
1886.09
EV/EBITDA
ACB
-6.68
ADAG
-5.72

Profitability

Gross Margin
ACB
36.03%
ADAG
100.0%
Operating Margin
ACB
2.32%
ADAG
-32283.6%
Profit Margin
ACB
-22.51%
ADAG
0.0%
ROE
ACB
-15.51%
ADAG
-63.26%
ROA
ACB
-4.36%
ADAG
-24.89%

Growth

Revenue Growth
ACB
6.8%
ADAG
--
Earnings Growth
ACB
-94.7%
ADAG
--

Financial Health

Debt/Equity
ACB
0.18
ADAG
0.18
Current Ratio
ACB
3.06
ADAG
2.29
Quick Ratio
ACB
1.05
ADAG
2.2

Dividends

Dividend Yield
ACB
--
ADAG
--
Payout Ratio
ACB
0.0%
ADAG
0.0%

AI Verdict

ACB BEARISH

Aurora Cannabis Inc. (ACB) exhibits severe financial distress signals, underscored by a Piotroski F-Score of 1/9—indicating extreme weakness in operational and financial health. The absence of an Altman Z-Score and persistent negative profitability metrics (ROE: -15.51%, ROA: -4.36%) suggest high bankruptcy risk, especially given the company's negative earnings and declining cash flow. Despite a low price-to-book (0.49) and price-to-sales (0.52), the stock trades at a significant discount due to deteriorating fundamentals and a 96.9% 5-year decline. The lack of analyst coverage and neutral insider activity further erode confidence in near-term recovery.

Strengths
Low price-to-book ratio (0.49) suggests potential undervaluation on a balance sheet basis
Strong gross margin (36.03%) indicates efficient production and cost control
High current ratio (3.06) reflects strong short-term liquidity
Risks
Piotroski F-Score of 1/9 indicates severe financial distress and poor operational performance
Negative ROE (-15.51%) and ROA (-4.36%) reflect persistent unprofitability
Earnings growth has collapsed by -94.70% YoY, with a -93.60% Q/Q decline
ADAG BULLISH

ADAG's Piotroski F-Score of 4/9 indicates weak financial health, with negative profitability and high operating losses, but the company shows strong earnings surprise momentum and improving Q/Q EPS growth. Despite a lack of Altman Z-Score and Graham Number, the stock trades at a premium valuation (Price/Sales: 1886.09) due to high growth expectations in a sector with elevated average revenue growth. Insider sentiment is neutral, and analyst target price suggests significant upside potential. The recent 1-year return of +109.6% and strong quarterly beat rate support a bullish technical and earnings narrative.

Strengths
Strong earnings surprise history with 3 out of last 4 quarters beating estimates by an average of 39.09%
Improving Q/Q EPS growth of +58.3% and year-over-year EPS growth of +40.0%
High gross margin of 100.0% indicating strong product-level pricing power or low cost structure
Risks
Piotroski F-Score of 4/9 signals weak financial health, with negative ROE (-63.26%), ROA (-24.89%), and operating margin (-32,283.60%)
No positive operating cash flow or free cash flow; high reliance on external financing
Price/Sales ratio of 1886.09 is extremely elevated, indicating extreme growth premium

Compare Another Pair

ACB vs ADAG: Head-to-Head Comparison

This page compares Aurora Cannabis Inc. (ACB) and Adagene Inc. (ADAG) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile